Who has already signed up?
ESMO gratefully acknowledges the valuable contribution the following organisations have made to ESMO Sarcoma & GIST 2020. (As of December 2019):
Aadi Bioscience is a clinical stage biopharmaceutical company with an investigational mTOR inhibitor, nab-sirolimus (nanoparticle albumin-bound sirolimus, ABI-009), that recently completed a registration trial. Aadi has active clinical programs in various cancers and non-oncology conditions, in which the mTOR pathway is a key driver due to activations or mutations.
- Display space No. 5
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments.
- Display space No. 4
Clinigen is a global pharmaceutical and services company with a unique combination of business focused on providing access to medicines to improve the quality of people's lives around the world. Clinigen's mission is to deliver the right medicine to the right patient at the right time operating an international platform of medicine supply: clinical trials, unlicensed medicines and commercial medicines.
- Display space No. 3
PharmaMar is a biopharmaceutical company focused on oncology, which takes inspiration from the sea to discover molecules with antitumor activity. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar develops and commercializes Yondelis® in Europe, along with Aplidin®, approved for the Australian market.
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company’s approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.
Standard Educational Grant
Deciphera Pharmaceuticals is focused on improving the lives of cancer patients. We use our understanding of kinase biology together with a proprietary switch control inhibitor platform to purposefully design compounds that maintain kinases in an inactive conformation. Using this platform, we’ve developed a pipeline of drug candidates designed to improve outcomes for cancer patients.